No recent analyst price targets found for RTSN.
Latest News for RTSN
Retension Pharmaceuticals Announces Pricing of Initial Public Offering
FALLS CHURCH, Va., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Retension Pharmaceuticals, Inc. (Nasdaq: RTSN) (“Retension” or the “Company”), a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases, announced today the pricing of its upsized initial public offering of 3,750,000 shares of its common stock at an initial public offering price…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for RTSN.
U.S. House Trading
No House trades found for RTSN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.